Raymedica
Raymedica is to develop innovative solutions
About Raymedica
In 1990, a company named Raymedica was founded with a focus on a complex medical problem: degenerative disc disease. The company set out to develop and manufacture artificial spinal discs, aiming to provide an alternative to traditional treatments. Their core technology centered on nucleus arthroplasty, a method designed to preserve motion in the spine for patients suffering from disc herniation and degenerative conditions. For years, Raymedica worked on its specialized medical devices, attracting investment from notable players in the venture capital and medical technology space, including Medtronic and J.F. Shea Company. The company’s work represented a specific bet on motion preservation technology as a future standard in spine surgery. This journey reached its defining moment not through an IPO, but through an acquisition. On August 15, 2008, the company was acquired by Centinel Spine, a company focused on spinal solutions. The acquisition marked the end of Raymedica's independent journey, integrating its unique artificial disc technology into the portfolio of a larger, strategic buyer. This move allowed Raymedica's innovations to be carried forward within a broader commercial platform, concluding its chapter as a standalone entity.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 1990
- Headquarters
- Minneapolis, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 41.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Orthopedic, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2003 | $10M | $40M | Stephens Group · Viscogliosi Brothers · Shea Ventures · Chartwell Capital | — |
Growth signals
Latest recorded traffic for Raymedica is 0 monthly website visits. Raymedica's team grew 41.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Viscogliosi Brothers
Stephens Group
Shea Ventures- CCChartwell Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Raymedica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Raymedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






